Mason Wells

Deltanoid Pharmaceuticals, Inc. is a biopharmaceutical company based in Madison, Wisconsin, dedicated to the research, development, and commercialization of therapies for various human diseases, particularly focusing on renal diseases, osteoporosis, and skin conditions. Founded in 1999, the company specializes in vitamin D analogs and related compounds, aiming to advance selected therapies through the early stages of drug development. Notable products include DP001, designed for treating secondary hyperparathyroidism in chronic kidney disease patients undergoing hemodialysis, and DP006 for acne treatment. Deltanoid seeks partnerships for the later stages of development and commercialization, and it currently has an agreement with Novadiol, Inc. to develop a vitamin D therapy. Through its innovative approach, the company aims to enhance health outcomes for patients by unlocking the potential of vitamin D receptor-targeted therapies.

Gala Biotech, established in 1996 and located in Middleton, Wisconsin, specializes in biopharmaceutical manufacturing and molecular biology. The company, which has grown to over 40 employees, including 16 PhDs, is known for its proprietary GPEx® technology, which facilitates the rapid creation of stable, high-expressing mammalian cell lines for various gene products. Originally focused on producing pharmaceutical proteins in the milk of transgenic cows, Gala has adapted its gene insertion technology to support the increasing demand for the discovery and stable expression of therapeutic proteins. This technology plays a crucial role in helping biotech researchers overcome the challenges associated with clinical development. To enhance its capabilities, Gala has established a 43,000 square-foot facility dedicated to GPEx®-based cell line development and cGMP-compliant protein production, reinforcing its commitment to meeting the needs of its biopharmaceutical partners.